Novo Nordisk extends rebound on Eli Lilly trial results: are investors reversing positions?

Novo Nordisk shares surged over 5% on Friday, extending gains, after Eli Lilly's oral obesity drug candidate, orforglipron, presented trial results showing 12.4% weight loss and a less competitive side-effect profile, falling short of analyst expectations (15%) and Novo's established treatments. This outcome prompted a reversal of investor positions, notably unwinding 'long LLY, short Novo' trades, and significantly improved the perceived competitive standing of Novo Nordisk, which had recently seen a 35% stock decline. While some analysts upgraded Novo, Goldman Sachs maintains that Lilly's drug retains long-term commercial potential despite the short-term market overreaction.

Analysis

Novo Nordisk shares experienced a significant two-day rally, gaining over 5% on Friday, directly following the release of clinical trial data for Eli Lilly's oral obesity drug, orforglipron. The market's reaction was driven by Lilly's results falling short of expectations; the drug achieved a 12.4% average weight loss, below the anticipated 15% and trailing the 14.9% efficacy of Novo's injectable Wegovy. This outcome, coupled with a less competitive side-effect profile, prompted a rapid unwinding of a prevalent investor strategy of being 'long' Eli Lilly and 'short' Novo Nordisk, catching many market participants on the wrong side of the trade. The event marks a sharp reversal in fortune for Novo Nordisk, which had seen its stock decline 35% recently amid a profit warning and leadership changes. While some analysts, like Intron Health, upgraded Novo to "hold" from "sell" on renewed optimism for its oral semaglutide, they also cautioned that the total addressable market for obesity might be smaller than estimated. In contrast, Goldman Sachs argued the market overreacted, maintaining that Lilly's orforglipron remains a commercially attractive asset with global scalability and a manageable side-effect profile, suggesting its long-term potential is intact despite the short-term sentiment hit.

Key Decisions for Investors

• The violent unwinding of the 'long LLY, short NVO' trade highlights the risk of crowded positioning; investors should reassess exposure to this pairs trade as it is now subject to extreme volatility based on clinical news flow.
• For Novo Nordisk, the improved competitive perception may justify holding or accumulating positions, but this must be balanced against the stock's recent volatility and analyst warnings about the overall market size and potential pressure on profit margins.
• The pullback in Eli Lilly's stock could present a buying opportunity for long-term investors who believe the market has overreacted, but this requires acknowledging Novo's strengthened competitive position and tolerating near-term negative sentiment.
• Investors in the obesity drug sector must treat clinical trial results as primary catalysts and should be prepared for significant price swings in both stocks as further comparative data on efficacy and safety becomes available.